Lenaldekar

Research use only, not for human use.

Lenaldekar inhibits T-cell expansion and autoimmune encephalomyelitis.

Lenaldekar inhibits T-cell expansion and autoimmune encephalomyelitis. Lenaldekar causes dephosphorylation of members of the PI3 kinase/AKT/mTOR pathway and delays sensitive cells in late mitosis.(In Vitro):Lenaldekar could inhibit myelin specific T cell responses through the insulin-like growth factor-1 receptor (IGF-1R) pathway. Alteration of this pathway led to marked reduction in T cell proliferation and expansion. Blocking this pathway could account for the observed decreases in clinical signs and inflammatory demyelinating disease, which was accompanied by axonal preservation.(In Vivo):Relapsing-remitting experimental autoimmune encephalomyelitis was induced through active immunization of SJL/J mice with a myelin proteolipid protein peptide. The therapeutic efficacy of Lenaldekar treatment was evaluated via daily clinical score, cross-sectional ex vivo diffusion basis spectrum imaging examination and histological analysis. Lenaldekar greatly reduced relapse severity and protected white matter integrity in these experimental autoimmune encephalomyelitis mice. Diffusion basis spectrum imaging-derived axial diffusivity, radial diffusivity and restricted diffusion tensor fraction accurately reflected axonal injury, myelin integrity and inflammation-associated cellularity change, respectively.

——

——

LDK

Cytoskeleton/Cell Adhesion Molecules

Akt

——

——

——

418800-15-4

286.338

C18H14N4

>98% (HPLC)

——

N(\N=C\c1c[nH]c2ccccc12)c1cccc2cccnc12

——

(-20℃)

With Ice Pack

≥ 2 years